​

Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TVTX Stock Forecast

Travere Therapeutics stock forecast is as follows: an average price target of $21.75 (represents a 6.36% upside from TVTX’s last price of $20.45) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.

TVTX Price Target

The average price target for Travere Therapeutics (TVTX) is $21.75 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $12.00. This represents a potential 6.36% upside from TVTX's last price of $20.45.

TVTX Analyst Ratings

Buy

According to 15 Wall Street analysts, Travere Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TVTX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (80.00%), 3 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Travere Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Liisa BaykoEvercore ISI$33.00$17.5088.57%61.37%
Oct 21, 2024Mohit BansalWells Fargo$27.00$17.8751.09%32.03%
Oct 10, 2024Liisa BaykoEvercore ISI$30.00$18.0766.02%46.70%
Oct 09, 2024Jason ZemanskyBank of America Securities$20.00$15.2131.49%-2.20%
Oct 01, 2024Carter GouldBarclays$18.00$13.9928.66%-11.98%
Sep 27, 2024Vamil DivanGuggenheim$23.00$15.0452.93%12.47%
Sep 27, 2024Ed ArceH.C. Wainwright$18.00$15.0419.68%-11.98%
Sep 27, 2024Greg HarrisonBank of America Securities$18.00$14.0128.48%-11.98%
Sep 10, 2024Ed NashCanaccord Genuity$23.00$12.7081.17%12.47%
Sep 09, 2024Vamil DivanGuggenheim$12.50$6.3198.10%-38.88%
Aug 28, 2024Nicole GabreskiPiper Sandler$12.00$8.9633.93%-41.32%
Aug 02, 2024Ed ArceH.C. Wainwright$10.00$4.62116.45%-51.10%
May 07, 2024Ed NashCanaccord Genuity$9.00$3.28174.39%-55.99%
Apr 24, 2024Ed ArceH.C. Wainwright$9.50$2.74246.72%-53.55%
Dec 05, 2022Wells Fargo$28.00$20.0839.44%36.92%

The latest Travere Therapeutics stock forecast, released on Oct 31, 2024 by Liisa Bayko from Evercore ISI, set a price target of $33.00, which represents a 88.57% increase from the stock price at the time of the forecast ($17.50), and a 61.37% increase from TVTX last price ($20.45).

Travere Therapeutics Price Target by Period

1M3M12M
# Anlaysts-114
Avg Price Target-$33.00$18.79
Last Closing Price$20.45$20.45$20.45
Upside/Downside-100.00%61.37%-8.12%

In the current month, the average price target of Travere Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Travere Therapeutics's last price of $20.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jan 14, 2025GuggenheimBuyBuyHold
Oct 29, 2024Cowen & Co.BuyBuyHold
Oct 21, 2024Wells FargoSector OutperformSector OutperformHold
Oct 21, 2024Wells FargoBuyOverweightUpgrade
Oct 16, 2024WedbushSector OutperformSector OutperformHold
Oct 16, 2024ScotiabankOutperformInitialise
Oct 10, 2024Evercore ISIOutperformOutperformHold
Oct 09, 2024WedbushOutperformOutperformHold
Oct 01, 2024BarclaysOverweightOverweightHold
Sep 27, 2024StephensOverweightOverweightHold
Sep 27, 2024Leerink PartnersMarket PerformDowngrade
Sep 27, 2024Morgan StanleyOverweightUpgrade
Sep 27, 2024GuggenheimBuyBuyHold
Sep 27, 2024H.C. WainwrightBuyBuyHold
Sep 27, 2024Bank of America SecuritiesBuyBuyHold
Sep 10, 2024Canaccord GenuityBuyBuyHold
Sep 09, 2024GuggenheimBuyUpgrade
Sep 06, 2024CitigroupBuyBuyHold
Sep 06, 2024H.C. WainwrightBuyBuyHold
Aug 30, 2024Evercore ISIOutperformOutperformHold
Aug 28, 2024Piper SandlerNeutralNeutralHold
Aug 02, 2024WedbushBuyBuyHold
Aug 02, 2024Piper SandlerNeutralNeutralHold
Aug 02, 2024WedbushOutperformOutperformHold
Aug 02, 2024H.C. WainwrightBuyBuyHold
Aug 02, 2024BarclaysOverweightOverweightHold
May 28, 2024William BlairMarket PerformMarket PerformHold
May 07, 2024Canaccord GenuityBuyBuyHold
Apr 24, 2024H.C. WainwrightBuyBuyHold
Apr 17, 2024Wells FargoBuyBuyHold
Mar 13, 2024Wells FargoBuyBuyHold
Feb 16, 2024WedbushBuyBuyHold
Jan 18, 2024Sandler O'NeillBuyBuyHold
Dec 05, 2023CitigroupBuyUpgrade
Sep 22, 2023Wells FargoOverweightEqual-WeightDowngrade
Sep 21, 2023William BlairMarket PerformDowngrade
Sep 19, 2023Evercore ISIOutperformOutperformHold
Feb 21, 2023Piper SandlerOverweightInitialise
Feb 21, 2023WedbushOutperformUpgrade
Dec 05, 2022Wells FargoOverweightInitialise
Oct 14, 2022H.C. WainwrightBuyBuyHold

Travere Therapeutics's last stock rating was published by Guggenheim on Jan 14, 2025. The company gave TVTX a "Buy" rating, the same as its previous rate.

Travere Therapeutics Financial Forecast

Travere Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$37.09M$59.70M$56.99M$55.87M$53.50M$54.17M$48.49M$57.25M$68.22M$54.62M$47.41M$50.98M$51.14M$48.43M$47.77M$46.69M$44.37M
Avg Forecast$236.80M$202.40M$166.30M$135.90M$110.03M$90.27M$82.50M$69.01M$72.00M$60.87M$50.40M$43.46M$41.69M$57.33M$53.56M$50.61M$53.01M$54.12M$49.63M$52.19M$57.80M$60.93M$50.33M$50.09M$51.66M$47.84M$47.59M$43.43M$46.02M$45.29M
High Forecast$266.06M$227.41M$186.85M$152.70M$123.63M$101.42M$92.70M$76.42M$85.20M$60.95M$50.40M$43.46M$44.27M$131.96M$60.18M$56.86M$70.38M$54.12M$49.63M$52.19M$57.80M$60.93M$50.33M$50.09M$51.66M$47.84M$47.59M$43.43M$46.02M$45.29M
Low Forecast$174.57M$149.21M$122.60M$100.19M$81.12M$66.54M$60.82M$50.14M$62.35M$60.78M$50.40M$43.46M$39.31M$15.17M$39.48M$37.31M$40.58M$54.12M$49.63M$52.19M$57.80M$60.93M$50.33M$50.09M$51.66M$47.84M$47.59M$43.43M$46.02M$45.29M
# Analysts333344461155481366555111211109987655
Surprise %-------------0.65%1.11%1.13%1.05%0.99%1.09%0.93%0.99%1.12%1.09%0.95%0.99%1.07%1.02%1.10%1.01%0.98%

Travere Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $41.69M, with a low forecast of $39.31M, and a high forecast of $44.27M. TVTX's average Quarter revenue forecast represents a 12.39% increase compared to the company's last Quarter revenue of $37.09M (Sep 23).

Travere Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts333344461155481366555111211109987655
EBITDA-------------$-89.24M$-85.69M$-67.01M$-65.03M$-54.86M$-50.99M$-49.65M$-42.15M$-8.96M$-25.98M$-33.57M$-17.36M$-6.24M$-11.23M$-7.63M$-11.11M$-12.09M
Avg Forecast$-196.92M$-168.31M$-138.29M$-113.01M$-91.50M$-75.06M$-68.61M$-57.39M$-59.88M$-50.62M$-41.91M$-51.39M$-34.67M$-47.68M$-44.54M$-46.72M$-34.03M$-36.24M$-33.24M$-42.47M$-38.71M$-40.81M$-33.71M$-21.40M$-34.60M$-32.04M$-31.87M$-29.08M$-30.82M$-30.33M
High Forecast$-145.17M$-124.08M$-101.95M$-83.31M$-67.46M$-55.34M$-50.58M$-41.70M$-51.85M$-50.55M$-41.91M$-41.11M$-32.69M$-12.61M$-32.83M$-37.38M$-27.22M$-36.24M$-33.24M$-33.98M$-38.71M$-40.81M$-33.71M$-17.12M$-34.60M$-32.04M$-31.87M$-29.08M$-30.82M$-30.33M
Low Forecast$-221.26M$-189.11M$-155.38M$-126.98M$-102.81M$-84.34M$-77.08M$-63.55M$-70.85M$-50.69M$-41.91M$-61.67M$-36.81M$-109.74M$-50.04M$-56.06M$-40.83M$-36.24M$-33.24M$-50.97M$-38.71M$-40.81M$-33.71M$-25.68M$-34.60M$-32.04M$-31.87M$-29.08M$-30.82M$-30.33M
Surprise %-------------1.87%1.92%1.43%1.91%1.51%1.53%1.17%1.09%0.22%0.77%1.57%0.50%0.19%0.35%0.26%0.36%0.40%

undefined analysts predict TVTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Travere Therapeutics's previous annual EBITDA (undefined) of $NaN.

Travere Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts333344461155481366555111211109987655
Net Income-------------$150.74M$-85.63M$-86.33M$-65.82M$-69.66M$-67.03M$-75.97M$-51.57M$-35.64M$-39.01M$-53.87M$-121.62M$-22.55M$-26.07M$808.00K$-30.26M$-36.49M
Avg Forecast$110.45M$58.33M$32.67M$10.89M$-4.56M$-21.89M$-28.22M$-40.56M$-44.92M$-52.04M$-61.52M$-59.48M$-90.04M$-82.79M$-84.67M$-54.07M$-43.38M$-73.45M$-72.76M$-49.16M$-57.02M$-43.53M$-52.96M$-27.35M$-33.33M$-39.97M$-35.65M$-43.56M$-45.61M$-58.79M
High Forecast$128.19M$67.71M$37.92M$12.64M$-3.00M$-14.41M$-18.58M$-31.54M$-35.19M$-34.26M$-40.50M$-47.58M$-60.26M$2.77B$-55.74M$-43.26M$-34.71M$-73.45M$-72.76M$-39.33M$-57.02M$-43.53M$-52.96M$-21.88M$-33.33M$-39.97M$-35.65M$-43.56M$-45.61M$-58.79M
Low Forecast$72.71M$38.41M$21.51M$7.17M$-5.29M$-25.41M$-32.76M$-50.32M$-57.65M$-60.41M$-71.41M$-71.38M$-109.89M$-2.24B$-98.27M$-64.89M$-52.06M$-73.45M$-72.76M$-58.99M$-57.02M$-43.53M$-52.96M$-32.82M$-33.33M$-39.97M$-35.65M$-43.56M$-45.61M$-58.79M
Surprise %--------------1.82%1.01%1.60%1.52%0.95%0.92%1.55%0.90%0.82%0.74%1.97%3.65%0.56%0.73%-0.02%0.66%0.62%

Travere Therapeutics's average Quarter net income forecast for Dec 23 is $-90.04M, with a range of $-109.89M to $-60.26M. TVTX's average Quarter net income forecast represents a -159.73% decrease compared to the company's last Quarter net income of $150.74M (Sep 23).

Travere Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts333344461155481366555111211109987655
SG&A-------------$67.80M$74.04M$72.25M$62.92M$57.52M$52.98M$46.79M$42.08M$36.06M$34.97M$36.78M$35.74M$31.95M$34.97M$33.14M$27.53M$29.78M
Avg Forecast$234.24M$200.21M$164.50M$134.43M$108.85M$89.29M$81.61M$68.26M$71.22M$60.21M$49.85M$36.63M$41.24M$56.71M$52.98M$33.30M$35.39M$50.73M$46.52M$30.27M$54.18M$57.11M$47.18M$18.67M$48.42M$44.84M$44.61M$40.70M$43.14M$42.45M
High Forecast$263.19M$224.96M$184.83M$151.05M$122.30M$100.33M$91.69M$75.60M$84.28M$60.29M$49.85M$43.96M$43.79M$130.53M$59.53M$39.96M$42.47M$50.73M$46.52M$36.33M$54.18M$57.11M$47.18M$22.41M$48.42M$44.84M$44.61M$40.70M$43.14M$42.45M
Low Forecast$172.68M$147.60M$121.27M$99.10M$80.24M$65.83M$60.16M$49.60M$61.68M$60.13M$49.85M$29.31M$38.88M$15.00M$39.06M$26.64M$28.31M$50.73M$46.52M$24.22M$54.18M$57.11M$47.18M$14.94M$48.42M$44.84M$44.61M$40.70M$43.14M$42.45M
Surprise %-------------1.20%1.40%2.17%1.78%1.13%1.14%1.55%0.78%0.63%0.74%1.97%0.74%0.71%0.78%0.81%0.64%0.70%

Travere Therapeutics's average Quarter SG&A projection for Dec 23 is $41.24M, based on 8 Wall Street analysts, with a range of $38.88M to $43.79M. The forecast indicates a -39.17% fall compared to TVTX last annual SG&A of $67.80M (Sep 23).

Travere Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts333344461155481366555111211109987655
EPS-------------$1.98$-0.00$-1.27$-1.03$-1.09$-1.05$-1.20$-0.84$-0.59$-0.64$-0.96$-2.37$-0.44$-0.58$0.02$-0.70$-0.85
Avg Forecast$1.42$0.75$0.42$0.14$-0.06$-0.28$-0.36$-0.52$-0.58$-0.67$-0.79$-0.96$-1.16$-1.06$-1.09$-1.20$-1.13$-0.95$-0.94$-0.87$-0.74$-0.56$-0.68$-0.52$-0.43$-0.52$-0.46$-0.56$-0.59$-0.76
High Forecast$1.65$0.87$0.49$0.16$-0.04$-0.19$-0.24$-0.41$-0.45$-0.44$-0.52$-0.63$-0.77$35.55$-0.72$-0.79$-0.79$-0.95$-0.94$-0.87$-0.74$-0.56$-0.68$-0.52$-0.43$-0.52$-0.46$-0.56$-0.59$-0.76
Low Forecast$0.93$0.49$0.28$0.09$-0.07$-0.33$-0.42$-0.65$-0.74$-0.78$-0.92$-1.11$-1.41$-28.74$-1.26$-1.39$-1.62$-0.95$-0.94$-0.87$-0.74$-0.56$-0.68$-0.52$-0.43$-0.52$-0.46$-0.56$-0.59$-0.76
Surprise %--------------1.86%0.00%1.06%0.91%1.15%1.12%1.38%1.14%1.05%0.94%1.84%5.51%0.85%1.26%-0.04%1.19%1.12%

According to 8 Wall Street analysts, Travere Therapeutics's projected average Quarter EPS for Dec 23 is $-1.16, with a low estimate of $-1.41 and a high estimate of $-0.77. This represents a -158.47% decrease compared to TVTX previous annual EPS of $1.98 (Sep 23).

Travere Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$1.94$33.861645.36%Buy
KROSKeros Therapeutics$11.37$101.00788.30%Buy
GPCRStructure Therapeutics$30.75$99.00221.95%Buy
ANABAnaptysBio$17.42$49.83186.05%Buy
STOKStoke Therapeutics$10.51$26.50152.14%Buy
LEGNLegend Biotech$36.10$89.60148.20%Buy
APLSApellis Pharmaceuticals$29.47$70.80140.24%Buy
IDYAIDEAYA Biosciences$23.94$52.38118.80%Buy
CYTKCytokinetics$48.65$90.0084.99%Buy
RNAAvidity Biosciences$31.92$59.0084.84%Buy
PCVXVaxcyte$88.67$148.8067.81%Buy
RVMDRevolution Medicines$40.92$67.6765.37%Buy
COGTCogent Biosciences$9.30$14.5055.91%Buy
PTGXProtagonist Therapeutics$38.21$57.3350.04%Buy
MGTXMeiraGTx$6.22$9.0044.69%Buy
NUVLNuvalent$85.52$114.8034.24%Buy
TVTXTravere Therapeutics$20.45$21.756.36%Buy
AKROAkero Therapeutics$54.00$50.00-7.41%Buy

TVTX Forecast FAQ

Is Travere Therapeutics a good buy?

Yes, according to 15 Wall Street analysts, Travere Therapeutics (TVTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 80.00% of TVTX's total ratings.

What is TVTX's price target?

Travere Therapeutics (TVTX) average price target is $21.75 with a range of $12 to $33, implying a 6.36% from its last price of $20.45. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Travere Therapeutics stock go up soon?

According to Wall Street analysts' prediction for TVTX stock, the company can go up by 6.36% (from the last price of $20.45 to the average price target of $21.75), up by 61.37% based on the highest stock price target, and down by -41.32% based on the lowest stock price target.

Can Travere Therapeutics stock reach $30?

TVTX's highest twelve months analyst stock price target of $33 supports the claim that Travere Therapeutics can reach $30 in the near future.

What are Travere Therapeutics's analysts' financial forecasts?

Travere Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $351.81M (high $394.17M, low $258.62M), average EBITDA is $-293M (high $-215M, low $-328M), average net income is $-95.225M (high $-67.535M, low $-114M), average SG&A $348.01M (high $389.92M, low $255.83M), and average EPS is $-1.224 (high $-0.868, low $-1.463). TVTX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $741.4M (high $833.03M, low $546.56M), average EBITDA is $-617M (high $-455M, low $-693M), average net income is $212.34M (high $246.45M, low $139.79M), average SG&A $733.39M (high $824.03M, low $540.65M), and average EPS is $2.73 (high $3.17, low $1.8).

Did the TVTX's actual financial results beat the analysts' financial forecasts?

Based on Travere Therapeutics's last annual report (Dec 2022), the company's revenue was $212.02M, beating the average analysts forecast of $208.96M by 1.47%. Apple's EBITDA was $-244M, beating the average prediction of $-146M by 67.36%. The company's net income was $-278M, beating the average estimation of $-239M by 16.64%. Apple's SG&A was $220.21M, beating the average forecast of $162.91M by 35.17%. Lastly, the company's EPS was $-4.37, beating the average prediction of $-3.891 by 12.32%. In terms of the last quarterly report (Sep 2023), Travere Therapeutics's revenue was $37.1M, missing the average analysts' forecast of $57.33M by -35.30%. The company's EBITDA was $-89.241M, beating the average prediction of $-47.678M by 87.17%. Travere Therapeutics's net income was $150.74M, missing the average estimation of $-82.791M by -282.07%. The company's SG&A was $67.8M, beating the average forecast of $56.71M by 19.55%. Lastly, the company's EPS was $1.98, missing the average prediction of $-1.064 by -286.01%